Pneumonia Drug Development Pipeline Review, 2017

This report provides an overview of the pipeline landscape for pneumonia disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Community acquired pneumonia is pneumonia contracted by a person who has had little contact with the healthcare system, with common symptoms including cough, fever and shortness of breath. Risk factors include chronic lung disease, cigarette smoking, immune system problems and surgery.

Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted. Signs and symptoms include malaise, fever, chills, rigor, cough, dyspnea, and chest pain, but in ventilated patients, pneumonia usually manifests as worsening oxygenation and increased tracheal secretions.

Finally, ventilator associated pneumonia is pneumonia that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such the disease typically affects critically ill patients and increases the risk of mortality. Signs and symptoms include fever or low body temperature, new purulent sputum and hypoxemia.

The size of these pipelines ranges from 20 products in community acquired pneumonia to 39 in hospital acquired pneumonia. Across all three of these indications bacterial targets such as DNA gyrase and ribosomal DNA are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

– Which companies are the most active within the pipeline for pneumonia therapeutics?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in the field of pneumonia?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Pneumonia Report Coverage 8

2.2 Community Acquired Pneumonia - Overview 8

2.3 Hospital Acquired Pneumonia (HAP) - Overview 8

2.4 Ventilator Associated Pneumonia (VAP) - Overview 8

3 Therapeutics Development 9

3.1 Community Acquired Pneumonia 9

3.2 Hospital Acquired Pneumonia (HAP) 13

3.3 Ventilator Associated Pneumonia (VAP) 19

4 Therapeutics Assessment 24

4.1 Community Acquired Pneumonia 24

4.2 Hospital Acquired Pneumonia (HAP) 30

4.3 Ventilator Associated Pneumonia (VAP) 37

5 Companies Involved in Therapeutics Development 44

5.1 Community Acquired Pneumonia 44

5.2 Hospital Acquired Pneumonia (HAP) 51

5.3 Ventilator Associated Pneumonia (VAP) 64

6 Dormant Projects 75

6.1 Community Acquired Pneumonia 75

6.2 Hospital Acquired Pneumonia (HAP) 76

6.3 Ventilator Associated Pneumonia (VAP) 77

7 Discontinued Products 78

7.1 Community Acquired Pneumonia 78

7.2 Hospital Acquired Pneumonia (HAP) 78

7.3 Ventilator Associated Pneumonia (VAP) 79

8 Product Development Milestones 80

8.1 Community Acquired Pneumonia 80

8.2 Hospital Acquired Pneumonia (HAP) 95

8.3 Ventilator Associated Pneumonia (VAP) 109

9 Appendix 122

9.1 Methodology 122

9.2 Coverage 122

9.3 Secondary Research 122

9.4 Primary Research 122

9.5 Expert Panel Validation 122

9.6 Contact Us 123

9.7 Disclaimer 123

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Community Acquired Pneumonia 9

Table 2: Number of Products under Development by Companies Community Acquired Pneumonia 11

Table 3: Products under Development by Companies Community Acquired Pneumonia 12

Table 4: Number of Products under Development for Hospital Acquired Pneumonia (HAP) 13

Table 5: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP) 15

Table 6: Products under Development by Companies Hospital Acquired Pneumonia (HAP) 16

Table 7: Number of Products under Development for Ventilator Associated Pneumonia (VAP) 19

Table 8: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP) 21

Table 9: Products under Development by Companies Ventilator Associated Pneumonia (VAP) 22

Table 10: Number of Products by Stage and Target Community Acquired Pneumonia 25

Table 11: Number of Products by Stage and Mechanism of Action Community Acquired Pneumonia 26

Table 12: Number of Products by Stage and Route of Administration Community Acquired Pneumonia 28

Table 13: Number of Products by Stage and Molecule Type Community Acquired Pneumonia 29

Table 14: Number of Products by Stage and Target Hospital Acquired Pneumonia (HAP) 31

Table 15: Number of Products by Stage and Mechanism of Action Hospital Acquired Pneumonia (HAP) 33

Table 16: Number of Products by Stage and Route of Administration Hospital Acquired Pneumonia (HAP) 35

Table 17: Number of Products by Stage and Molecule Type Hospital Acquired Pneumonia (HAP) 36

Table 18: Number of Products by Stage and Target Ventilator Associated Pneumonia (VAP) 38

Table 19: Number of Products by Stage and Mechanism of Action Ventilator Associated Pneumonia (VAP) 40

Table 20: Number of Products by Stage and Route of Administration Ventilator Associated Pneumonia (VAP) 42

Table 21: Number of Products by Stage and Molecule Type Ventilator Associated Pneumonia (VAP) 43

Table 22: Community Acquired Pneumonia – Pipeline by Aridis Pharmaceuticals LLC 44

Table 23: Community Acquired Pneumonia – Pipeline by Biotest AG 44

Table 24: Community Acquired Pneumonia – Pipeline by InflaRx GmbH 45

Table 25: Community Acquired Pneumonia – Pipeline by ioGenetics Inc 45

Table 26: Community Acquired Pneumonia – Pipeline by Kyorin Pharmaceutical Co Ltd 46

Table 27: Community Acquired Pneumonia – Pipeline by Melinta Therapeutics Inc 46

Table 28: Community Acquired Pneumonia – Pipeline by Merck & Co Inc 47

Table 29: Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics AG 47

Table 30: Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc 48

Table 31: Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd 48

Table 32: Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Company Ltd 49

Table 33: Community Acquired Pneumonia – Pipeline by Tetraphase Pharmaceuticals Inc 50

Table 34: Community Acquired Pneumonia – Pipeline by TiGenix NV 50

Table 35: Community Acquired Pneumonia – Pipeline by Wockhardt Ltd 51

Table 36: Hospital Acquired Pneumonia (HAP) – Pipeline by Achaogen Inc 51

Table 37: Hospital Acquired Pneumonia (HAP) – Pipeline by Adenium Biotech ApS 52

Table 38: Hospital Acquired Pneumonia (HAP) – Pipeline by Aridis Pharmaceuticals LLC 52

Table 39: Hospital Acquired Pneumonia (HAP) – Pipeline by AstraZeneca Plc 53

Table 40: Hospital Acquired Pneumonia (HAP) – Pipeline by Bayer AG 54

Table 41: Hospital Acquired Pneumonia (HAP) – Pipeline by Cardeas Pharma Corp 54

Table 42: Hospital Acquired Pneumonia (HAP) – Pipeline by Destiny Pharma Ltd 55

Table 43: Hospital Acquired Pneumonia (HAP) – Pipeline by Dong-A Socio Holdings Co Ltd 55

Table 44: Hospital Acquired Pneumonia (HAP) – Pipeline by Lakewood-Amedex Inc 56

Table 45: Hospital Acquired Pneumonia (HAP) – Pipeline by MedImmune LLC 56

Table 46: Hospital Acquired Pneumonia (HAP) – Pipeline by Meiji Seika Pharma Co Ltd 57

Table 47: Hospital Acquired Pneumonia (HAP) – Pipeline by Melinta Therapeutics Inc 57

Table 48: Hospital Acquired Pneumonia (HAP) – Pipeline by Merck & Co Inc 58

Table 49: Hospital Acquired Pneumonia (HAP) – Pipeline by Motif Bio Plc 59

Table 50: Hospital Acquired Pneumonia (HAP) – Pipeline by Nabriva Therapeutics AG 59

Table 51: Hospital Acquired Pneumonia (HAP) – Pipeline by Polyphor Ltd 60

Table 52: Hospital Acquired Pneumonia (HAP) – Pipeline by Sealife PHARMA GMBH 60

Table 53: Hospital Acquired Pneumonia (HAP) – Pipeline by Shionogi & Co Ltd 61

Table 54: Hospital Acquired Pneumonia (HAP) – Pipeline by Tetraphase Pharmaceuticals Inc 61

Table 55: Hospital Acquired Pneumonia (HAP) – Pipeline by The Medicines Company 62

Table 56: Hospital Acquired Pneumonia (HAP) – Pipeline by Theravance Biopharma Inc 62

Table 57: Hospital Acquired Pneumonia (HAP) – Pipeline by Wockhardt Ltd 63

Table 58: Hospital Acquired Pneumonia (HAP) – Pipeline by Zavante Therapeutics Inc 63

Table 59: Ventilator Associated Pneumonia (VAP) – Pipeline by Achaogen Inc 64

Table 60: Ventilator Associated Pneumonia (VAP) – Pipeline by Adenium Biotech ApS 64

Table 61: Ventilator Associated Pneumonia (VAP) – Pipeline by Aridis Pharmaceuticals LLC 65

Table 62: Ventilator Associated Pneumonia (VAP) – Pipeline by AstraZeneca Plc 66

Table 63: Ventilator Associated Pneumonia (VAP) – Pipeline by Bayer AG 66

Table 64: Ventilator Associated Pneumonia (VAP) – Pipeline by Cardeas Pharma Corp 67

Table 65: Ventilator Associated Pneumonia (VAP) – Pipeline by Destiny Pharma Ltd 67

Table 66: Ventilator Associated Pneumonia (VAP) – Pipeline by Dong-A Socio Holdings Co Ltd 68

Table 67: Ventilator Associated Pneumonia (VAP) – Pipeline by Lakewood-Amedex Inc 68

Table 68: Ventilator Associated Pneumonia (VAP) – Pipeline by MedImmune LLC 69

Table 69: Ventilator Associated Pneumonia (VAP) – Pipeline by Meiji Seika Pharma Co Ltd 69

Table 70: Ventilator Associated Pneumonia (VAP) – Pipeline by Merck & Co Inc 70

Table 71: Ventilator Associated Pneumonia (VAP) – Pipeline by Motif Bio Plc 70

Table 72: Ventilator Associated Pneumonia (VAP) – Pipeline by Nabriva Therapeutics AG 70

Table 73: Ventilator Associated Pneumonia (VAP) – Pipeline by Polyphor Ltd 71

Table 74: Ventilator Associated Pneumonia (VAP) – Pipeline by Shionogi & Co Ltd 71

Table 75: Ventilator Associated Pneumonia (VAP) – Pipeline by Tetraphase Pharmaceuticals Inc 72

Table 76: Ventilator Associated Pneumonia (VAP) – Pipeline by The Medicines Company 73

Table 77: Ventilator Associated Pneumonia (VAP) – Pipeline by Theravance Biopharma Inc 73

Table 78: Ventilator Associated Pneumonia (VAP) – Pipeline by Wockhardt Ltd 74

Table 79: Ventilator Associated Pneumonia (VAP) – Pipeline by Zavante Therapeutics Inc 74

Table 80: Community Acquired Pneumonia – Dormant Projects 75

Table 81: Hospital Acquired Pneumonia (HAP) – Dormant Projects 76

Table 82: Ventilator Associated Pneumonia (VAP) – Dormant Projects 77

Table 83: Community Acquired Pneumonia – Discontinued Products 78

Table 84: Hospital Acquired Pneumonia (HAP) – Discontinued Products 78

Table 85: Ventilator Associated Pneumonia (VAP) – Discontinued Products 79

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Community Acquired Pneumonia 9

Figure 2: Number of Products under Development by Companies Community Acquired Pneumonia 10

Figure 3: Number of Products under Development for Hospital Acquired Pneumonia (HAP) 13

Figure 4: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP) 14

Figure 5: Number of Products under Development for Ventilator Associated Pneumonia (VAP) 19

Figure 6: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP) 20

Figure 7: Number of Products by Targets Community Acquired Pneumonia 24

Figure 8: Number of Products by Stage and Targets Community Acquired Pneumonia 24

Figure 9: Number of Products by Mechanism of Actions Community Acquired Pneumonia 25

Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions Community Acquired Pneumonia 26

Figure 11: Number of Products by Routes of Administration Community Acquired Pneumonia 27

Figure 12: Number of Products by Stage and Routes of Administration Community Acquired Pneumonia 27

Figure 13: Number of Products by Molecule Types Community Acquired Pneumonia 28

Figure 14: Number of Products by Stage and Molecule Types Community Acquired Pneumonia 29

Figure 15: Number of Products by Top 10 Targets Hospital Acquired Pneumonia (HAP) 30

Figure 16: Number of Products by Stage and Top 10 Targets Hospital Acquired Pneumonia (HAP) 30

Figure 17: Number of Products by Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP) 32

Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP) 32

Figure 19: Number of Products by Routes of Administration Hospital Acquired Pneumonia (HAP) 34

Figure 20: Number of Products by Stage and Routes of Administration Hospital Acquired Pneumonia (HAP) 34

Figure 21: Number of Products by Molecule Types Hospital Acquired Pneumonia (HAP) 35

Figure 22: Number of Products by Stage and Molecule Types Hospital Acquired Pneumonia (HAP) 36

Figure 23: Number of Products by Top 10 Targets Ventilator Associated Pneumonia (VAP) 37

Figure 24: Number of Products by Stage and Top 10 Targets Ventilator Associated Pneumonia (VAP) 37

Figure 25: Number of Products by Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP) 39

Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP) 39

Figure 27: Number of Products by Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP) 41

Figure 28: Number of Products by Stage and Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP) 41

Figure 29: Number of Products by Molecule Types Ventilator Associated Pneumonia (VAP) 42

Figure 30: Number of Products by Stage and Molecule Types Ventilator Associated Pneumonia (VAP) 43

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports